Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PPIB | P23284 | 2/20 | 0.37 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.36 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8018111 | 0.91 | PAX8 (0.55) | PAX8MAPK1BRD4CREBBPNPSR1 | |
| SCHEMBL6914487 | 0.84 | CYP3A4 (0.39) | PAX8MAPK1ALDH1A1CYP3A4TDP1 | |
| SCHEMBL19998349 | 0.84 | MT-CO2 (0.46) | PAX8MAPK1ALDH1A1CYP3A4TDP1 | |
| SCHEMBL19998347 | 0.84 | MT-CO2 (0.46) | PAX8MAPK1ALDH1A1CYP3A4TDP1 | |
| SCHEMBL3364970 | 0.84 | PAX8 (0.50) | PAX8MAPK1BRD4CREBBPNPSR1 | |
| SCHEMBL14384381 | 0.84 | PAX8 (0.50) | PAX8ALDH1A1CYP3A4BRD4CREBBP | |
| SCHEMBL18067970 | 0.83 | PPIB (0.40) | PAX8MAPK1ALDH1A1CYP3A4TDP1 | |
| SCHEMBL19531657 | 0.83 | PAX8 (0.47) | PAX8MAPK1ALDH1A1BRD4CREBBP | |
| SCHEMBL24448783 | 0.82 | NPSR1 (0.58) | PAX8MAPK1ALDH1A1BRD4CREBBP | |
| SCHEMBL4015896 | 0.82 | PAX8 (0.49) | PAX8ALDH1A1TDP1BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105837493-B | The synthetic method and its intermediate of Nintedanib | 东南大学 | 2018-12-14 | — | — | CN | claimed |
| CN-105837493-A | A synthetic method of Nintedanib and an intermediate of Nintedanib | 东南大学 | 2016-08-10 | — | — | CN | claimed |
| US-12569563-B2 | Selective HDAC6 degraders and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4667461-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON S AND GAUCHER DISEASE | Children's Hospital Medical Center (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250382274-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S AND GAUCHER DISEASE | CHILDRENS HOSPITAL MED CT (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-04-10 | — | — | US | disclosed |
| EP-4486390-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | Terremoto Biosciences, Inc (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240246980-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. | 2024-07-25 | — | — | US | disclosed |
| WO-2024092222-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20230406812-A1 | NOVEL AMINOAROMATIC COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES COMPRISING SAME AS ACTIVE INGREDIENT | INSTITUTE FOR BASIC SCIENCE (KR) | 2023-12-21 | — | — | US | disclosed |
| EP-4245749-A1 | NOVEL AMINOAROMATIC COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES COMPRISING SAME AS ACTIVE INGREDIENT | Institute for Basic Science (KR) | 2023-09-20 | — | — | EP | disclosed |
| EP-2090571-A1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009039127-A1 | URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
| EP-1438053-B1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-09-10 | — | — | EP | disclosed |
| US-7173028-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-02-06 | — | — | US | disclosed |
| US-20060100211-A1 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-05-11 | — | — | US | disclosed |
| CN-1665789-A | Diaminopyrimidinecarboxa mide derivative | YAMANOUCHI PHARMA CO LTD (JP) | 2005-09-07 | — | — | CN | disclosed |
| EP-1438053-A1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-07-21 | — | — | EP | disclosed |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-11 | — | — | US | disclosed |
| WO-2003032997-A1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | AKT1, AKT1S1, AKT2 | PAX8 3642/4885MAPK1 232/4885ALDH1A1 4472/4885 |
| US-20060100211-A1 | Pyrimidine derivatives | TYMP, TYMS, DPYD | PAX8 3975/4885MAPK1 839/4885ALDH1A1 252/4885 |
| US-20240246980-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS | MRGPRX1, MRGPRX2, MRGPRX4 | PAX8 3020/4885MAPK1 1069/4885ALDH1A1 3740/4885 |
| US-20250382274-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S AND GAUCHER DISEASE | GBA1, GAA, GBA2 | PAX8 3763/4885MAPK1 3672/4885ALDH1A1 1073/4885 |
| US-20230406812-A1 | NOVEL AMINOAROMATIC COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES COMPRISING SAME AS ACTIVE INGREDIENT | HTT, SNCA, ATXN2 | PAX8 3914/4885MAPK1 2059/4885ALDH1A1 1074/4885 |
| US-12569563-B2 | Selective HDAC6 degraders and methods of use thereof | HDAC6, HDAC1, HDAC11 | PAX8 4149/4885MAPK1 3197/4885ALDH1A1 1630/4885 |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | COL1A1, MKI67, INSR | PAX8 4868/4885MAPK1 420/4885ALDH1A1 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.